Hormonal
Soy isoflavones (specifically genistein and daidzein) reduce adipose tissue and improve lipid profiles in rodents through estrogen receptor (ER) and PPAR-mediated pathways, but these effects are highly dependent on sex, age, and dosage, with high pharmacological doses often required to achieve in vitro-relevant concentrations in vivo.
Soy isoflavones are not a reliable weight-loss tool for humans at typical dietary or supplemental doses. While rodent studies show fat reduction at very high, pharmacological doses, these effects are inconsistent, sex-specific, and sometimes promote fat gain in young males. The concentrations needed to see benefits in cell cultures are far higher than what humans achieve through diet. Focus on whole soy foods for general health, but do not rely on isoflavone supplements for obesity treatment.
Most animal models used to elucidate the effects of isoflavones on obesity are rodent strains with either genetically or diet-induced obesity... dietary genistein at 1000 mg/kg diet does not affect body weight... dietary isoflavones significantly decrease body weight and adipose tissue... genistein is adipogenic in young, immature (4-wk-old) male mice... pharmacologic doses inhibited adipose deposition in both sexes.
Why this rating
The paper is a review of in vitro and rodent studies; human clinical data is sparse and inconclusive, and in vitro concentrations often exceed physiological levels.
Source
The Effects of Soy Isoflavones on Obesity
Anne Ørgaard et al. · Experimental Biology and Medicine · 2008
DOI 10.3181/0712-mr-347
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →